Zhang Hui, Wang Lingxia, Wu Huanwen
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
MRL Global Medical Affairs, MSD China, Shanghai, China.
Front Oncol. 2023 Dec 19;13:1276085. doi: 10.3389/fonc.2023.1276085. eCollection 2023.
Ovarian cancer (OC) is the eighth most common cancer in women, but the mild, non-specific clinical presentation in early stages often prevents diagnosis until progression to advanced-stage disease, contributing to the high mortality associated with OC. While serum cancer antigen 125 (CA-125) has been successfully used as a blood-borne marker and is routinely monitored in patients with OC, CA-125 testing has limitations in sensitivity and specificity and does not provide direct information on important molecular characteristics that can guide treatment decisions, such as homologous recombination repair deficiency. We comprehensively review the literature surrounding methods based on liquid biopsies, which may provide improvements in sensitivity, specificity, and provide valuable additional information to enable early diagnosis, monitoring of recurrence/progression/therapeutic response, and accurate prognostication for patients with OC, highlighting applications of this research in China.
卵巢癌（OC）是女性中第八大常见癌症，但早期阶段轻微、非特异性的临床表现常常导致在病情进展到晚期之前无法确诊，这使得OC相关的死亡率居高不下。虽然血清癌抗原125（CA-125）已成功用作血液标志物，并在OC患者中常规监测，但CA-125检测在敏感性和特异性方面存在局限性，并且无法提供可指导治疗决策的重要分子特征的直接信息，例如同源重组修复缺陷。我们全面回顾了围绕液体活检方法的文献，这些方法可能在敏感性、特异性方面有所改进，并提供有价值的额外信息，以实现OC患者的早期诊断、复发/进展/治疗反应监测以及准确预后评估，同时突出该研究在中国的应用。
